August 27, 2014
Calithera files to raise up to $80 million in IPO
Tumor metabolism and immunology specialist Calithera Biosciences Inc. on Tuesday revealed plans to raise up to $80 million in a yet-to-price initial public offering (IPO). The company will debut on Nasdaq under the symbol CALA and said it would use proceeds from the offering to advance CB-839, its phase I glutaminase inhibitor for triple-negative breast cancer and multiple myeloma as well as a preclinical arginase inhibitor.
To read more, visit: http://www.bioworld.com/content/calithera-files-raise-80-million-ipo
By Michael Fitzhugh